Skip to main content
. Author manuscript; available in PMC: 2009 Feb 22.
Published in final edited form as: Eur J Neurol. 2007 Jul;14(7):801–808. doi: 10.1111/j.1468-1331.2007.01860.x

Table 3.

Saturated, monounsaturated and polyunsaturated fatty acids, across group of baseline compound muscle action potential (CMAP)

CMAP (<3 mV), (n = 129) CMAP (3–4 mV), (n = 206) CMAP (>4 mV), (n = 906) Beta+ SE Pa
Saturated fatty acids (%) 32.4 ± 3.0 32.4 ± 3.0 32.4 ± 2.8 0.041 ± 0.036 0.25
Monounsaturated fatty acids (%) 31.9 ± 3.5 31.1 ± 3.4 30.2 ± 3.8 −0.045 ± 0.28 0.10
Polyunsaturated fatty acids (%) 35.8 ± 4.8 36.5 ± 4.7 37.3 ± 5.0 0.012 ± 0.021 0.58
Omega-6 fatty acids (mg/l) 1020.0 ± 251.9 1040.4 ± 236.2 1065.0 ± 234.6 0.0007 ± 0.0004 0.09
 Linoleic acid (mg/l) 765.2 ± 196.1 769.1 ± 172.8 803.6 ± 179.4 0.001 ± 0.0005 0.06
 Arachidonic acid (mg/l) 251.2 ± 78.1 267.6 ± 86.4 269.9 ± 81.1 0.0009 ± 0.001 0.46
Omega-3 fatty acids (mg/l) 107.0 ± 42.8 107.3 ± 38.8 109.2 ± 41.2 0.266 ± 0.254 0.30
 Linolenic acid (mg/l) 14.9 ± 9.7 14.5 ± 10.4 14.8 ± 9.3 0.006 ± 0.01 0.56
 Eicosapentaenoic acid (mg/l) 19.7 ± 9.1 19.5 ± 7.4 19.9 ± 8.6 0.014 ± 0.011 0.21
 Docosahexaenoic acid (mg/l) 72.4 ± 31.1 73.3 ± 28.5 74.5 ± 30.5 0.0016 ± 0.003 0.62
Ratio n-6/n-3 10.5 ± 3.3 10.6 ± 3.6 10.6 ± 3.0 0.01 ± 0.03 0.64

Values are given as mean ± SD.

a

General linear model with CMAP considered as a continuous variable and adjusted for age, sex, body mass index, total cholesterol, triglycerides, diabetes and peripheral artery disease.